There are over 6 million people with heart failure in the United States. Other than delivering a baby, it’s the leading reason for an adult to be hospitalized in the United States. And for those age 65 and over, it’s the main reason to be hospitalized.
The question is what to do with patients who have advanced heart failure that impairs their daily life, such as getting out of breath walking a block or up a flight of stairs, but are not quite as bad as patients who are now eligible for transplant or put on a permanent LVAD heart pump.
The REVIVE-IT clinical trial will test the theory that patients like these will live longer and better with earlier implantation of a left ventricular assist device rather than treating them with medicine alone and waiting for very advanced stages of heart failure to develop.
Enrollment begins across the U.S.
- Advanced heart failure as characterized by New York Heart Association Class III Symptoms
- Reduced heart function with an left ventricular ejection fraction of 35% or less
- Chronic and well-established heart failure for at least one year
Heart transplantation is an enormous success for cardiovascular medicine in the last 30 years. However with 2,200 donor hearts available to transplant in the U.S. each year, transplantation can help very few of the millions with heart failure.
“We can’t make hearts – not yet anyway. But we can make pumps, and we can make as many as we need,” says cardiologist Keith Aaronson, M.D. “This study will go a long way toward helping us figure out how best to use them.”
Take the next step:
- Learn more about the REVIVE-IT study led by the U-M Frankel Cardiovascular Center.
- Watch a video of lead investigators Dr. Francis Pagani and Dr. Keith Aaronson explaining the study.
- Questions? Contact a study coordinator at CVCVolunteer@med.umich.edu, or 1-888-286-4420.
- Read Jerome Wilson’s story about living with an LVAD.
The University of Michigan Frankel Cardiovascular Center is home to one of the world’s largest and most experienced LVAD programs. Clinicians and researchers at the University of Michigan Heart Transplant Program and Center for Circulatory Support have provided leadership in the clinical investigation of most of the implantable circulatory support devices in use today.